What question did this study set out to answer?

March 7, 2026

Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis

Key Points

The research aims to determine the incidence of acne in patients with inflammatory bowel disease (IBD) treated with Janus kinase (JAK) inhibitors.
Conducted a systematic review and meta-analysis
Included studies reporting acne occurrences in IBD patients
Analyzed data on different subpopulations, including pediatrics and treatment phases
Acne incidence was significantly higher in patients treated with upadacitinib
The pediatric population displayed a particularly high incidence of acne
Higher occurrence of acne was noticed during the induction phase of JAK inhibitor treatment

Abstract

Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.

Bookmark

Cite This Study

Quraishi et al. (Wed,) studied this question.

synapsesocial.com/papers/69abc1b45af8044f7a4ea972 https://doi.org/https://doi.org/10.1093/ibd/izag032

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark